Implant Sciences Continues to Win ECAC Follow-on Orders as Austrian Airports Place Additional Orders for QS-B220s
Implant Sciences Corporation (OTCQB:IMSC), a leading manufacturer of explosives trace detection (ETD) and drugs trace detection solutions for homeland security applications, today announced that it has received a follow-on order for 16 additional QS-B220 Desktop Explosives Trace Detectors, for deployment to airports in Austria. Earlier this year, airports in Austria purchased and deployed 22 of Implant Sciences' QS-B220s for passenger and baggage checkpoint screening.
Over the past six months, Implant Sciences has announced a string of significant sales orders, after having successfully met the new European Civil Aviation Conference's (ECAC) standards for aviation screening of passengers and baggage. The QS-B220 was the first explosives trace detector to pass ECAC testing, which sets stringent standards for security equipment deployed across EU nations.
Global Aerial Imaging Industry 2016 Market Research Report
"Implant Sciences has experienced noteworthy success in the European market since the spring of 2015, leading to the most positive year in the company's history as manufacturer of explosives trace detectors," stated Dr. Bill McGann, CEO of Implant Sciences. "We are moving towards 2016 with a backlog of over $40 million, comprised of our ECAC and TSA orders. We have carefully planned for this rapid growth and scaled our production capability to allow us to meet the increased demand for our products."
"As the pioneer of non-rad IMS explosives trace detection, with thousands of units deployed around the world, we are pleased to see additional repeat customers emerging in the European aviation market," added Dr. Darryl Jones, Implant Sciences' Executive Vice President. "Our system's easy-to-use interface, low false alarm rate, and high performance continue to drive customers to choose our product."
About the QS-B220 Desktop Explosives Trace Detector
The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
Source : Implant Sciences Corporation - view original press release
May 1 - 4, 2017 - Las Vegas, United States